专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008144345A2 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO INSULIN GROWTH FACTOR-1 RECEPTOR MODULATORS 审中-公开
标题翻译：生物标记物和确定胰岛素生长因子-1受体调节剂敏感性的方法
公开(公告)号：WO2008144345A2
公开(公告)日：2008-11-27
申请号：PCT/US2008/063621
申请日：2008-05-15
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , HAN, Xia , HAFEZI, Rameh , CHEN, Jiwen , ROBINSON, Douglas, Michael , WITTENBERG, Gayle, M. , DONGRE, Ashok, Ramesh , CARBONI, Joan, M. , ATTAR, Ricardo, M. , HURLBURT, Warren , GOTTARDIS, Marco, M.
发明人： HUANG, Fei , HAN, Xia , HAFEZI, Rameh , CHEN, Jiwen , ROBINSON, Douglas, Michael , WITTENBERG, Gayle, M. , DONGRE, Ashok, Ramesh , CARBONI, Joan, M. , ATTAR, Ricardo, M. , HURLBURT, Warren , GOTTARDIS, Marco, M.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.
摘要翻译： IGF1R生物标志物可用于鉴定和监测将对治疗癌症治疗的治疗反应的哺乳动物的方法，其包括施用IGF1R调节剂，其中所述方法包括（a）将哺乳动物暴露于IGF1R调节剂和（b）在哺乳动物中测量所述至少一种生物标志物的水平，其中在（b）中测量的至少一种生物标志物的水平的差异与尚未暴露于IGF1R调节剂的哺乳动物中的生物标志物的水平相比表明哺乳动物将对治疗癌症的方法进行反应和（c）其中暴露于IGF1R调节剂后哺乳动物中的生物标志物的水平指示哺乳动物对治疗癌症的方法有治疗反应。

2. 发明申请

WO2016168143A1 IMMUNOASSAY FOR SOLUBLE PROGRAMMED DEATH-1 (sPD-1) PROTEIN 审中-公开
标题翻译：免疫编码死亡-1（sPD-1）蛋白质免疫
公开(公告)号：WO2016168143A1
公开(公告)日：2016-10-20
申请号：PCT/US2016/027025
申请日：2016-04-12
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： NI, Yan G. , YUAN, Xiling , PICCOLI, Steven P.
IPC分类号： G01N33/566 , G01N33/74
CPC分类号： G01N33/566 , G01N33/74
摘要： This disclosure provides a method for quantifying total soluble Programmed Death-1 (sPD-1) in a sample solution comprising the steps of performing a "sandwich" immunoassay on the sample solution and a series of reference solutions containing known quantities of sPD-1, wherein the immunoassay is performed using (a) a sPD-1 reference antigen in monomeric form; (b) a capture antibody that is capable of binding to sPD-1 in both monomeric and dimeric forms, which binding is essentially unaffected by the presence of the PD-1 ligands, PDL-1, PDL-2, and/or a therapeutic anti-PD-1 antibody; and (c) an electrochemiluminescent-labeled detection antibody that is capable of binding to sPD-1 in both monomeric and dimeric forms, which binding is to a different epitope on sPD-1 than the epitope bound by the capture Ab and is essentially unaffected by the presence of PDL-1, PDL-2 and/or a therapeutic anti-PD-1 Ab.
摘要翻译：本公开提供了一种用于量化样品溶液中的总可溶性程序死亡-1（sPD-1）的方法，包括以下步骤：在样品溶液上进行“夹心”免疫测定，以及一系列含有已知量的sPD-1，其中使用（a）单体形式的sPD-1参照抗原进行免疫测定; （b）能够以单体和二聚体形式结合sPD-1的捕获抗体，其结合基本上不受PD-1配体，PDL-1，PDL-2和/或治疗剂的存在的影响抗PD-1抗体; 和（c）电化学发光标记的检测抗体，其能够以单体和二聚体形式结合sPD-1，其结合到sPD-1上的不同表位，而不是被捕获Ab结合的表位，并且基本上不受 PDL-1，PDL-2和/或治疗性抗-PD-1Ab的存在。

3. 发明申请

WO2008115561A2 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS 审中-公开
公开(公告)号：WO2008115561A2
公开(公告)日：2008-09-25
申请号：PCT/US2008/003705
申请日：2008-03-21
申请人： BRISTOL-MYERS SQUIBB COMPANY , WU, Shujian , CHASALOW, Scott D. , LEE, Hyerim
发明人： WU, Shujian , CHASALOW, Scott D. , LEE, Hyerim
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q2600/118 , C12Q2565/501
摘要： Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone.

4. 发明申请

WO2011130354A1 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9 审中-公开
标题翻译：基于FIBRONECTIN的SCAFFOLD域蛋白质，包括PCSK9
公开(公告)号：WO2011130354A1
公开(公告)日：2011-10-20
申请号：PCT/US2011/032231
申请日：2011-04-13
申请人： BRISTOL-MYERS SQUIBB COMPANY , CAMPHAUSEN, Ray , CLOAD, Sharon T. , DAVIS, Jonathan H. , DENHEZ, Fabienne M. , SAEED-KOTHE, Amna , LIPOVSEK, Dasa , LOW, Chee Meng , MITCHELL, Tracy S. , RAKESTRAW, Ginger C. , RUSSO, Katie A. , LO, Ching-Hsiung Frederick , MIAO, Bowman , PARKER, Rex A. , SITKOFF, Doree F.
发明人： CAMPHAUSEN, Ray , CLOAD, Sharon T. , DAVIS, Jonathan H. , DENHEZ, Fabienne M. , SAEED-KOTHE, Amna , LIPOVSEK, Dasa , LOW, Chee Meng , MITCHELL, Tracy S. , RAKESTRAW, Ginger C. , RUSSO, Katie A. , LO, Ching-Hsiung Frederick , MIAO, Bowman , PARKER, Rex A. , SITKOFF, Doree F.
IPC分类号： C07K14/78 , C12N9/64 , A61K38/39
CPC分类号： C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
摘要： The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
摘要翻译：本发明涉及结合PCSK9的基于纤连蛋白的支架结构域蛋白。本发明还涉及创新的蛋白质在治疗应用中用于治疗动脉粥样硬化，高胆固醇血症和其它胆固醇相关疾病的用途。本发明还涉及包含这种蛋白质的细胞，编码这些蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。

5. 发明申请

WO2007117439A2 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICROTUBULE-STABILIZING AGENTS 审中-公开
公开(公告)号：WO2007117439A2
公开(公告)日：2007-10-18
申请号：PCT/US2007/008269
申请日：2007-03-30
申请人： BRISTOL-MYERS SQUIBB COMPANY , LEE, Hyerim , CLARK, Edwin, A. , WU, Shujian , XU, Li-An
发明人： LEE, Hyerim , CLARK, Edwin, A. , WU, Shujian , XU, Li-An
IPC分类号： G01N33/574 , G01N33/68 , C12Q1/68
CPC分类号： G01N33/57415 , G01N33/57484 , G01N33/57496 , G01N2800/52
摘要： Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone.

6. 发明申请

WO2018064094A1 ENANTIOSELECTIVE SYNTHESIS OF PYRROLOINDOLE COMPOUNDS 审中-公开
标题翻译：吡咯并吲哚化合物的对映体合成
公开(公告)号：WO2018064094A1
公开(公告)日：2018-04-05
申请号：PCT/US2017/053591
申请日：2017-09-27
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： SCHMIDT, Michael Anthony
IPC分类号： C07D209/10 , C07F7/18
CPC分类号： C07D209/10 , C07D209/12 , C07F7/1804
摘要： Compounds according to formula (I) or (II), wherein R 1 , R 2 , and R 3 are as defined in the specification, are versatile intermediates for the synthesis of DNA minor groove binder- alkylators having a cyclopropapyrroloindole (CPI) or seco -CPI alkylating subunit.
摘要翻译：根据式（I）或（II）的化合物，其中R 1，R 2和R 3分别代表氢，如说明书中所定义，是用于合成具有环丙基吡咯并吲哚（CPI）或seco-CPI烷基化亚基的DNA小沟结合剂 - 烷化剂的多功能中间体。

7. 发明申请

WO2018048975A1 USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-MESOTHELIN ANTIBODY IN CANCER TREATMENT 审中-公开
标题翻译：抗PD-1抗体与抗中间蛋白抗体联合治疗癌症的应用
公开(公告)号：WO2018048975A1
公开(公告)日：2018-03-15
申请号：PCT/US2017/050390
申请日：2017-09-07
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： SRIVASTAVA, Shivani , LATHERS, Deanne , VEZINA, Heather E. , CARDARELLI, Josephine M. , SABBATINI, Peter , WADE, Mark S. , PAN, Chin
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395 , A61K31/00 , A61K47/68
CPC分类号： C07K16/2818 , A61K31/454 , A61K39/395 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61P35/00 , C07K16/2839 , C07K16/30
摘要： A method of treating a tumor in a patient by administering to the patient a therapeutically effective amount of a combination of an anti-PD-1 antibody and an anti-mesothelin antibody-drug conjugate.
摘要翻译：通过给予患者治疗有效量的抗PD-1抗体和抗间皮素抗体 - 药物偶联物的组合来治疗患者的肿瘤的方法。 >

8. 发明申请

WO2017007985A1 TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND IL-6 审中-公开
标题翻译：使用抗PD-1抗体和IL-6的组合治疗癌症
公开(公告)号：WO2017007985A1
公开(公告)日：2017-01-12
申请号：PCT/US2016/041434
申请日：2016-07-08
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： LEWIS, Katherine E.
IPC分类号： A61K39/395 , A61K38/20 , C07K14/54 , C07K16/28
CPC分类号： C07K16/2827 , A61K38/204 , A61K39/395 , A61K2300/00
摘要： This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and, (b) IL-6.
摘要翻译：本公开提供了治疗患有癌症的受试者的方法，该方法包括向患者施用治疗有效量的：（a）抗癌剂，其是抗体或其抗原结合部分，其特异性结合于程序性死亡-1（PD-1）受体并抑制PD-1活性; 和（b）IL-6。

9. 发明申请

WO2008127526A8 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 MODULATORS 审中-公开
公开(公告)号：WO2008127526A8
公开(公告)日：2008-10-23
申请号：PCT/US2008/003258
申请日：2008-03-12
申请人： BRISTOL-MYERS SQUIBB COMPANY , WU, Shujian , AYERS, Mark David , HAN, Xia , YOGANATHAN, Suganthy , FARGNOLI, Joseph
发明人： WU, Shujian , AYERS, Mark David , HAN, Xia , YOGANATHAN, Suganthy , FARGNOLI, Joseph
IPC分类号： C12Q1/68
摘要： VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

10. 发明申请

WO2008109075A2 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO CTLA-4 ANTAGONISTS 审中-公开
标题翻译：生物标志物和确定对CTLA-4拮抗剂敏感性的方法
公开(公告)号：WO2008109075A2
公开(公告)日：2008-09-12
申请号：PCT/US2008/002863
申请日：2008-03-04
申请人： BRISTOL-MYERS SQUIBB COMPANY , TSUCHIHASHI, Zenta , HU, Beihong , JURE-KUNKEL, Maria
发明人： TSUCHIHASHI, Zenta , HU, Beihong , JURE-KUNKEL, Maria
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q2600/118 , C12Q2565/501
摘要： CTLA-4 biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an CTLA-4 antagonist, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker s, (b) exposing a biological sample from the mammal to the CTLA-4 antagonist, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
摘要翻译：可用于预测对治疗癌症的方法有治疗反应的哺乳动物的可能性的方法的CTLA-4生物标志物，其包括施用CTLA-4拮抗剂，其中所述方法包括（a）测量（b）将来自哺乳动物的生物样品暴露于CTLA-4拮抗剂，和（c）在暴露步骤（b）之后，在生物样品中测量所述哺乳动物中所述生物标志物的水平至少一种生物标志物，其中步骤（c）中测量的所述至少一种生物标志物的水平与步骤（a）中测量的所述至少一种生物标志物的水平相比的增加表明所述哺乳动物将对治疗反应的可能性增加治疗癌症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式